This promotional material is intended for UK Healthcare Professionals experienced in the diagnosis and treatment of Chronic Migraine. BOTOX® (botulinum toxin type A) Prescribing Information and adverse event reporting information can be found below.
Diagnosing and managing chronic migraine
Could your patients with chronic migraine benefit from treatment with BOTOX®?
CM: chronic migraine; CV: cardiovascular; ICHD: International Classification of Headache Disorders.
Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use. The BOTOX® Summary of Product Characteristics can be found here
By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
Date of preparation: January 2025. UK-BCM-240124.